This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tallini, G. Articles by Rosai, J. Search for Related Content PubMed PubMed Citation Articles by Tallini, G. Articles by Rosai, J.

American Journal of Pathology, Vol 144, 693-701, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation

G Tallini, DM Parham, P Dias, C Cordon-Cardo, PJ Houghton and J Rosai
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

Myogenic regulatory protein (MyoD1) is a DNA-binding nuclear protein that initiates myogenesis in mesenchymal stem cells. Its expression has proved a very sensitive marker of myogenic differentiation in malignant tumors of childhood. In this study, the reliability of MyoD1 expression as marker of skeletal muscle differentiation has been tested in 38 cases of adult-type sarcomas. Frozen sections were stained with the monoclonal antibody 5.8A (MAb 5.8A) developed against recombinant wild- type murine MyoD1. Routinely processed formalin-fixed sections from the same cases were reviewed and immunostained with a panel of antibodies commonly used to detect muscle differentiation: myoglobin, fast-myosin, desmin, muscle-specific actin, alpha-smooth muscle actin. Four cases positively stained with MAb 5.8A: three were high-grade spindle cell sarcomas, the fourth case was an alveolar soft-part sarcoma. Only tumors in which skeletal muscle histogenesis was inferred on the basis of histology and/or immunohistochemistry with conventional muscle markers stained positively for MAb 5.8A. All the other tumors tested, including leiomyosarcomas (11), liposarcomas, (10, including four dedifferentiated liposarcomas), fibrosarcomas (three), malignant fibrous histiocytomas (two), synovial sarcomas (two), and malignant peripheral nerve sheath tumors (two), were negative for MAb 5.8A. The high level of sensitivity and specificity of MyoD1 expression indicates the value of this marker in the diagnosis of soft tissue sarcomas.

This article has been cited by other articles:

				A L Folpe and A T Deyrup Alveolar soft-part sarcoma: a review and update. J. Clin. Pathol., November 1, 2006; 59(11): 1127 - 1132. [Abstract] [Full Text] [PDF]

				H. Kodama, T. Hirotani, Y. Suzuki, S. Ogawa, and K. Yamazaki Cardiomyogenic Differentiation in Cardiac Myxoma Expressing Lineage-Specific Transcription Factors Am. J. Pathol., August 1, 2002; 161(2): 381 - 389. [Abstract] [Full Text] [PDF]

				F. Thomas, J. F. Lipton, C. Barbera, V. J. Vigorita, and E. Bryk Primary Rhabdomyosarcoma of the Humerus : A Case Report and Review of the Literature J. Bone Joint Surg. Am., May 1, 2002; 84(5): 813 - 817. [Full Text] [PDF]

				P. Dias, B. Chen, B. Dilday, H. Palmer, H. Hosoi, S. Singh, C. Wu, X. Li, J. Thompson, D. Parham, et al. Strong Immunostaining for Myogenin in Rhabdomyosarcoma Is Significantly Associated with Tumors of the Alveolar Subclass Am. J. Pathol., February 1, 2000; 156(2): 399 - 408. [Abstract] [Full Text] [PDF]